Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Pan

Vascular Surgery Lancaster, OH Medical Doctor

NPI 1235316589 CMS profile 1195484

618 Pleasantville Rd, Suite 302, Lancaster, OH 43130

Open in the dashboard

General payments

$3,463

69 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Pan of Lancaster, OH is reported in the CMS Open Payments database as having received $3,463 across 69 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 41st percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,038 13
2024 General $1,511 10
2023 General $234 6
2022 General $80 3
2021 General $252 18
2020 General $119 8
2019 General $229 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Pan
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to James Pan were reported at $1,038. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year James Pan Vascular Surgery median Middle half National median
2019 $229 $796 $226–$2,363 $163
2020 $119 $348 $118–$1,110 $114
2021 $252 $471 $158–$1,421 $132
2022 $80 $725 $222–$2,183 $149
2023 $234 $836 $257–$2,440 $160
2024 $1,511 $909 $252–$2,619 $164
2025 $1,038 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Silk Road Medical, Inc. $1,317 4 payments
  2. W. L. Gore & Associates, Inc. $902 12 payments
  3. Philips Electronics North America Corporation $292 18 payments
  4. Globus Medical, Inc. $258 2 payments
  5. Smith+Nephew, Inc. $249 14 payments
  6. Janssen Pharmaceuticals, Inc $137 3 payments
  7. Spineology Inc. $93 1 payment
  8. Cardiovascular Systems Inc. $88 7 payments
  9. Medtronic, Inc. $27 2 payments
  10. AngioDynamics, Inc. $25 1 payment
  11. Other $74 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $1,774 6 payments
  2. Food and Beverage $1,552 60 payments
  3. Education $137 3 payments
Products named General payments · program years 2019–2025
  1. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $1,317 4 payments
  2. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $1,317 4 payments
  3. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $1,317 4 payments
  4. ENROUTE Transcarotid Stent $1,317 4 payments
  5. GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis $809 8 payments
  6. Lasers $167 9 payments
  7. XLIF $148 1 payment
  8. RELINE $148 1 payment
  9. XARELTO $137 3 payments
  10. GRAFIX PL $114 8 payments
  11. Other $934 35 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

247

Median for Vascular Surgery: 122

Drug cost

$42,741

Median for Vascular Surgery: $14,135

Branded share of claims

66.4%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 40 $28,237
Xarelto Rivaroxaban Brand 24 $12,655
Sps Sodium Polystyrene Sulfon/Sorb Brand 23 $1,002
Clopidogrel Clopidogrel Bisulfate Brand 55 $330
Rosuvastatin Calcium Generic 22 $199
Nystatin Generic 19 $161
Triamcinolone Acetonide Generic 17 $64
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 22 $55
Tramadol Hcl Generic 11 $19
Prednisone Generic 14 $18

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 109 billing codes

Paid by Medicare

$59,563

Medicare's payments for the services billed

Medicare patients

329

Average age 74

Services billed

564

153 women, 176 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 53%
Arthritis 52%
Chronic kidney disease 50%
Diabetes 48%
Heart failure 37%
Depression 32%
COPD 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

69 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record